论文部分内容阅读
为慢性活动性病毒性肝病确定最佳治疗方案乃是肝病治疗难题之一,困难的原因是乙型肝炎病毒(HBV)及患者的自身免疫参予发病过程。在此种情况下,若使用免疫系统抑制剂,有些学者认为可使病毒复制活性增强,并有可能导致肝癌,若使用免疫激活剂,虽可清除病毒,但又常常引起细胞溶解性征象。究竟采用何种方案,往往取决于医生本人的知识。根据病毒性肝病的病原学和病理学特点,作者对直接影响病毒复制同时又影响机体免疫系统的各种药物作了研究分析。
Determining the optimal regimen for chronic active viral liver disease is one of the challenges in the treatment of liver disease due to the involvement of autoimmunity in the pathogenesis of Hepatitis B virus (HBV) and the patient. Under such circumstances, some scholars believe that if the use of immune system inhibitors, viral replication activity and may lead to liver cancer, if the use of immune activators, although the virus can be removed, but often cause signs of cell lysis. What kind of programs are used, often depends on the doctor’s own knowledge. According to the etiological and pathological features of viral liver disease, the authors made a research analysis of various drugs that directly affect the viral replication and affect the immune system of the body.